Epidemiologic studies of H. pylori associated diseases – risk factors 

  1. Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Long-term peptic ulcer rebleeding risk estimation in patients undergoing haemodialysis: a 10-year nationwide cohort study. Gut. 2011 Aug;60(8):1038-42.  
  2. Wu CY, Wu MS, Kuo KN, Wang CB, Chen YJ, Lin JT. Effective reduction of gastric cancer risk with regular use of nonsteroidal anti-inflammatory drugs in Helicobacter pylori-infected patients. J Clin Oncol. 2010 Jun 20;28(18):2952-7. 
  3. Wu CY, Kuo KN, Wu MS, Chen YJ, Wang CB, Lin JT. Early Helicobacter pylori eradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology. 2009 Nov;137(5):1641-8.e1-2. 
  4. Wu CY, Wu CH, Wu MS, Wang CB, Cheng JS, Kuo KN, Lin JT. A nationwide population-based cohort study shows reduced hospitalization for peptic ulcer disease associated with H pylori eradication and proton pump inhibitor use. Clin Gastroenterol Hepatol. 2009 Apr;7(4):427-31. 
  5. Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, Gotoda T, Lin JT, You WC, Ng EK, Sung JJ; Asia Pacific Working Group on Gastric Cancer. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008 Mar;9(3):279-87.
  6. Lee YC, Lin JT, Wu HM, Liu TY, Yen MF, Chiu HM, Wang HP, Wu MS, Hsiu-Hsi Chen T. Cost-effectiveness analysis between primary and secondary preventive strategies for gastric cancer. Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):875-85. 
  7. Liou JM, Lin JT, Wang HP, Huang SP, Lee YC, Shun CT, Lin MT, Wu MS. The optimal age threshold for screening upper endoscopy for uninvestigated dyspepsia in Taiwan, an area with a higher prevalence of gastric cancer in young adults. Gastrointest Endosc. 2005 Jun;61(7):819-25.
  8. Wu MS, Lee WJ, Wang HH, Huang SP, Lin JT. A case-control study of association of Helicobacter pylori infection with morbid obesity in Taiwan. Arch Intern Med. 2005 Jul 11;165(13):1552-5. 
Treatment of Helicobacter pylori infection 
  1. Liou JM, Chen CC, Chen MJ, Chen CC, Chang CY, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH, Hsu YC, Tseng CH, Tseng PH, Wang HP, Yang UC, Shun CT, Lin JT, Lee YC*, Wu MS*, for the Helicobacter pylori Consortium. Sequential versus triple therapy in the first line treatment of Helicobacter pylori -A multicentre, open label, randomised trial. Lancet. 2013 Jan 19;381(9862):205-13. 
  2. Liou JM, Chen CC, Chen MJ, Chang CY, Fang YJ, Lee JY, Sheng WH, Wang HP, Wu MS, Lin JT. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother. 2011 Aug;66(8):1847-52.  
  3. Liou JM, Lin JT, Chang CY, Chen MJ, Cheng TY, Lee YC, Chen CC, Sheng WH, Wang HP, Wu MS. Levofloxacin-based and clarithromycin-based triple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with crossover design. Gut. 2010 May;59(5):572-8. 
  4. Liou JM, Chen CC, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee JY, Hsu SJ, Luo JC, Chang WH, Hsu YC, Tseng CH, Tseng PH, Wang HP, Yang UC, Shun CT, Wu JY, Lee YC, Lin JT, Wu MS*, on behave of the Helicobacter pylori Consortium. The Efficacy of Genotypic Resistance-Guided Sequential Therapy in the Third Line Treatment of Refractory Helicobacter pylori Infection- a Multicentre Clinical Trial. J Antimicrob Chemother. 2013 Feb;68(2):450-456. 
  5. Liou JM, Chang CY, Sheng WH, Wang YC, Chen MJ, Lee YC, Hung HW, Chian H, Chang SC, Wu MS, Lin JT. Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies. Antimicrob Agents Chemother. 2011 Mar;55(3):1123-9. 
Biomarkers of H. pylori associated disease
  1. Lee YC, Wang HP, Wang CP, Ko JY, Lee JM, Chiu HM, Lin JT, Yamashita S, Oka D, Watanabe N, Matsuda Y, Ushijima T, Wu MS (corresponding author). Revisit of Field Cancerization in Squamous Cell Carcinoma of Upper Aerodigestive Tract: Better Risk Assessment with Epigenetic Markers. Cancer Prev Res (Phila). 2011 Sep 27. [Epub ahead of print]
  2. Liou JM, Shun CT, Liang JT, Chiu HM, Chen MJ, Chen CC, Wang HP, Wu MS, Lin JT. Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. J Clin Endocrinol Metab. 2010 Apr;95(4):1717-25. 
  3. Liao WC, Lin JT, Wu CY, Huang SP, Lin MT, Wu AS, Huang YJ, Wu MS. Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma. Clin Cancer Res. 2008 Jan 15;14(2):428-34.
  4. Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH, Shih YT, Chen GH, Lin JT. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution. Clin Cancer Res. 2007 Apr 1;13(7):2054-60.
  5. Wu CY, Wu MS, Chiang EP, Wu CC, Chen YJ, Chen CJ, Chi NH, Chen GH, Lin JT. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut. 2007 Jun;56(6):782-9. 
Treatment of gastric acid related diseases- peptic ulcer disease and gastroesophageal reflux disease 
  1. Chen WY, Chang WL, Tsai YC, Cheng HC, Lu CC, Sheu BS. Double-dosed pantoprazole accelerates the sustained symptomatic response in overweight and obese patients with reflux esophagitis in Los Angeles grades A and B. Am J Gastroenterol. 2010 May;105(5):1046-52. 
  2. Lee YC, Yen AM, Tai JJ, Chang SH, Lin JT, Chiu HM, Wang HP, Wu MS, Chen TH. The effect of metabolic risk factors on the natural course of gastro-oesophageal reflux disease. Gut. 2009 Feb;58(2):174-81. 
Carcinogenesis of gastric cancer 
  1. Wu MS, Lin JT, Hsu PN, Lin CY, Hsieh YT, Chiu YH, Hsueh PR, Liao KW. Preferential induction of transforming growth factor-beta production in gastric epithelial cells and monocytes by Helicobacter pylori soluble proteins. J Infect Dis. 2007 Nov 1;196(9):1386-93. 
  2. Cheng TY, Lin JT, Chen LT, Shun CT, Wang HP, Lin MT, Wang TE, Cheng AL, Wu MS. Association of T-cell regulatory gene polymorphisms with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma. J Clin Oncol. 2006 Jul 20;24(21):3483-9.
  3. Chuang MH, Wu MS, Lo WL, Lin JT, Wong CH, Chiou SH. The antioxidant protein alkylhydroperoxide reductase of Helicobacter pylori switches from a peroxide reductase to a molecular chaperone function. Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2552-7.
Detection and Pathogenesis of Colorectal Cancer 
  1. Liou JM, Shun CT, Liang JT, et al. Plasma insulin-like growth factor-binding protein-2 levels as diagnostic and prognostic biomarker of colorectal cancer. J Clin Endocrinol Metab 2010;95:1717-25. 
  2. Chiu HM, Chang CY, Chen CC, et al. A prospective comparative study of narrow-band imaging, chromoendoscopy, and conventional colonoscopy in the diagnosis of colorectal neoplasia. Gut 2007;56:373-9.  
  3. Chiang TH, Lee YC, Tu CH, Chiu HM, Wu MS. Performance of the immunochemical fecal occult blood test in predicting lesions in the lower gastrointestinal tract. CMAJ 2011;183:1474-81.
  4. Chiu HM, Lin JT, Lee YC, et al. Different bowel preparation schedule leads to different diagnostic yield of proximal and nonpolypoid colorectal neoplasm at screening colonoscopy in average-risk population. Dis Colon Rectum 2011;54:1570-7 
  5. Liou JM, Wu MS, Lin JT, et al. Loss of imprinting of insulin-like growth factor II is associated with increased risk of proximal colon cancer. Eur J Cancer 2007;43:1276-82.  
  6. Chiu HM, Lin JT, Chen TH, et al. Elevation of C-reactive protein level is associated with synchronous and advanced colorectal neoplasm in men. Am J Gastroenterol 2008;103:2317-25.